Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4

L. Martín-Carbonero, M. Puoti, J. García-Samaniego, A. De Luca, E. Losada, G. Quinzan, R. Bruno, A. Mariño, M. González, M. Núñez, V. Soriano

Research output: Contribution to journalArticlepeer-review

Abstract

Hepatitis C virus (HCV) genotypes 1 and 4 respond less well to pegylated interferon (pegIFN) plus ribavirin (RBV) therapy. For this reason most studies merge these two genotypes when assessing virological response. However, in most trials the HCV genotype 4 population is rather small, and conclusions are mainly derived from what occurs in HCV-1 patients. All HCV-4 patients coinfected with HIV who received pegIFN plus RBV in two different multicentre studies, PRESCO and ROMANCE, conducted respectively in Spain and Italy, were retrospectively analyzed. Baseline plasma HCV-RNA, proportion of patients with HCV-RNA 2 logs at week 12 (early virological response, EVR) were all assessed as predictors of sustained virological response (SVR). Overall, 75 patients (60 men) were evaluated. Median age was 40 years and median CD4 count 598 cells/mm 3; 49% had plasma HIV-RNA

Original languageEnglish
Pages (from-to)710-715
Number of pages6
JournalJournal of Viral Hepatitis
Volume15
Issue number10
DOIs
Publication statusPublished - Oct 2008

Keywords

  • HCV genotype 4
  • Hepatitis C
  • HIV
  • Liver
  • Pegylated interferon
  • Ribavirin

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases
  • Virology

Fingerprint Dive into the research topics of 'Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4'. Together they form a unique fingerprint.

Cite this